Quantitative analysis for C4 Therapeutics, Inc. (CCCC) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (56.0) (grade B). 28 signals analyzed (23 differentiated alt-data).
CCCC stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $2.95 | $2.73 | $2.75 |
| 2026-05-08 | $3.08 | $2.92 | $2.95 |
| 2026-05-20 | $3.39 | $3.14 | $3.28 |
| 2026-06-02 | $4.58 | $4.13 | $4.34 |
| 2026-06-12 | $4.25 | $3.84 | $3.90 |
| 2026-06-25 | $4.45 | $4.21 | $4.40 |
| 2026-07-08 | $4.37 | $3.72 | $4.19 |
| 2026-07-20 | $3.73 | $3.47 | $3.55 |
| 2026-07-30 | $3.69 | $3.52 | $3.66 |
| 2026-08-12 | $3.99 | $3.84 | $3.90 |
| 2026-08-24 | $4.14 | $3.81 | $4.10 |
| 2026-09-03 | $3.85 | $3.70 | $3.74 |
How C4 Therapeutics, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| IVA | Inventiva S.A. | $267M | — |
| ZURA | Zura Bio Limited | $266M | 38.0 |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $264M | 65.0 |
| FBRX | Forte Biosciences, Inc. | $282M | — |
View all Health Care stocks by valuation and signals →
C4 Therapeutics, Inc. (CCCC) scores Buy (56.0), with no measured dimension below 53. Its highest are competitive moat at 98, analyst consensus at 74, ML forecast at 72, across 4 measured dimensions. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 98 |
| analyst consensus | 74 |
| ML forecast | 72 |
| technicals | 53 |
StoQuant analyzes 28 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on C4 Therapeutics, Inc. (CCCC): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/CCCC"><img src="https://stoquant.com/badge/CCCC.svg" alt="C4 Therapeutics, Inc. (CCCC) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.